Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

1.

Clinical and antiviral efficacy of an ophthalmic formulation of dexamethasone povidone-iodine in a rabbit model of adenoviral keratoconjunctivitis.

Clement C, Capriotti JA, Kumar M, Hobden JA, Foster TP, Bhattacharjee PS, Thompson HW, Mahmud R, Liang B, Hill JM.

Invest Ophthalmol Vis Sci. 2011 Jan 21;52(1):339-44. doi: 10.1167/iovs.10-5944. Print 2011 Jan.

PMID:
20702820
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

A combination povidone-iodine 0.4%/dexamethasone 0.1% ophthalmic suspension in the treatment of adenoviral conjunctivitis.

Pelletier JS, Stewart K, Trattler W, Ritterband DC, Braverman S, Samson CM, Liang B, Capriotti JA.

Adv Ther. 2009 Aug;26(8):776-83. doi: 10.1007/s12325-009-0062-1.

PMID:
19756415
[PubMed - indexed for MEDLINE]
3.

The in vitro and in vivo evaluation of ddC as a topical antiviral for ocular adenovirus infections.

Romanowski EG, Yates KA, Gordon YJ.

Invest Ophthalmol Vis Sci. 2009 Nov;50(11):5295-9. doi: 10.1167/iovs.08-3286. Epub 2009 Jun 10.

PMID:
19516011
[PubMed - indexed for MEDLINE]
Free Article
4.

Topical corticosteroids reverse the antiviral effect of topical cidofovir in the Ad5-inoculated New Zealand rabbit ocular model.

Romanowski EG, Araullo-Cruz T, Gordon YJ.

Invest Ophthalmol Vis Sci. 1997 Jan;38(1):253-7.

PMID:
9019458
[PubMed - indexed for MEDLINE]
Free Article
5.

Clinical evaluation of local ocular toxicity in candidate anti-adenoviral agents in vivo.

Inoue H, Sonoda KH, Ishikawa M, Kadonosono K, Uchio E.

Ophthalmologica. 2009;223(4):233-8. doi: 10.1159/000205585. Epub 2009 Mar 5.

PMID:
19262070
[PubMed - indexed for MEDLINE]
6.

Antiviral prophylaxis with twice daily topical cidofovir protects against challenge in the adenovirus type 5/New Zealand rabbit ocular model.

Romanowski EG, Yates KA, Gordon YJ.

Antiviral Res. 2001 Dec;52(3):275-80.

PMID:
11675144
[PubMed - indexed for MEDLINE]
7.

The antiviral resistance and replication of cidofovir-resistant adenovirus variants in the New Zealand White rabbit ocular model.

Romanowski EG, Gordon YJ, Araullo-Cruz T, Yates KA, Kinchington PR.

Invest Ophthalmol Vis Sci. 2001 Jul;42(8):1812-5.

PMID:
11431446
[PubMed - indexed for MEDLINE]
Free Article
8.

Efficacy of topical cidofovir on multiple adenoviral serotypes in the New Zealand rabbit ocular model.

Romanowski EG, Gordon YJ.

Invest Ophthalmol Vis Sci. 2000 Feb;41(2):460-3.

PMID:
10670476
[PubMed - indexed for MEDLINE]
Free Article
9.

N-chlorotaurine is an effective antiviral agent against adenovirus in vitro and in the Ad5/NZW rabbit ocular model.

Romanowski EG, Yates KA, Teuchner B, Nagl M, Irschick EU, Gordon YJ.

Invest Ophthalmol Vis Sci. 2006 May;47(5):2021-6.

PMID:
16639011
[PubMed - indexed for MEDLINE]
Free Article
10.

The cotton rat model for adenovirus ocular infection: antiviral activity of cidofovir.

Kaneko H, Mori S, Suzuki O, Iida T, Shigeta S, Abe M, Ohno S, Aoki K, Suzutani T.

Antiviral Res. 2004 Jan;61(1):63-6.

PMID:
14670595
[PubMed - indexed for MEDLINE]
11.

A controlled trial of povidone-iodine to treat infectious conjunctivitis in children.

Isenberg SJ, Apt L, Valenton M, Del Signore M, Cubillan L, Labrador MA, Chan P, Berman NG.

Am J Ophthalmol. 2002 Nov;134(5):681-8.

PMID:
12429243
[PubMed - indexed for MEDLINE]
12.

Evaluation of Cidofovir (HPMPC, GS-504) against adenovirus type 5 infection in vitro and in a New Zealand rabbit ocular model.

de Oliveira CB, Stevenson D, LaBree L, McDonnell PJ, Trousdale MD.

Antiviral Res. 1996 Jul;31(3):165-72.

PMID:
8811201
[PubMed - indexed for MEDLINE]
13.

The effects of cidofovir 1% with and without cyclosporin a 1% as a topical treatment of acute adenoviral keratoconjunctivitis: a controlled clinical pilot study.

Hillenkamp J, Reinhard T, Ross RS, Böhringer D, Cartsburg O, Roggendorf M, De Clercq E, Godehardt E, Sundmacher R.

Ophthalmology. 2002 May;109(5):845-50.

PMID:
11986086
[PubMed - indexed for MEDLINE]
14.

Efficacy of topical cobalt chelate CTC-96 against adenovirus in a cell culture model and against adenovirus keratoconjunctivitis in a rabbit model.

Epstein SP, Pashinsky YY, Gershon D, Winicov I, Srivilasa C, Kristic KJ, Asbell PA.

BMC Ophthalmol. 2006 Jun 5;6:22.

PMID:
16753060
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Comparative antiviral efficacies of cidofovir, trifluridine, and acyclovir in the HSV-1 rabbit keratitis model.

Romanowski EG, Bartels SP, Gordon YJ.

Invest Ophthalmol Vis Sci. 1999 Feb;40(2):378-84.

PMID:
9950596
[PubMed - indexed for MEDLINE]
Free Article
16.

Efficacy of topical immunoglobulins against experimental adenoviral ocular infection.

Nwanegbo EC, Romanowski EG, Gordon YJ, Gambotto A.

Invest Ophthalmol Vis Sci. 2007 Sep;48(9):4171-6.

PMID:
17724203
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Topical HPMPC inhibits adenovirus type 5 in the New Zealand rabbit ocular replication model.

Gordon YJ, Romanowski EG, Araullo-Cruz T.

Invest Ophthalmol Vis Sci. 1994 Nov;35(12):4135-43.

PMID:
7960596
[PubMed - indexed for MEDLINE]
Free Article
18.

Effects of diclofenac or ketorolac on the inhibitory activity of cidofovir in the Ad5/NZW rabbit model.

Romanowski EG, Gordon YJ.

Invest Ophthalmol Vis Sci. 2001 Jan;42(1):158-62.

PMID:
11133861
[PubMed - indexed for MEDLINE]
Free Article
19.

Topical treatment of acute adenoviral keratoconjunctivitis with 0.2% cidofovir and 1% cyclosporine: a controlled clinical pilot study.

Hillenkamp J, Reinhard T, Ross RS, Böhringer D, Cartsburg O, Roggendorf M, De Clercq E, Godehardt E, Sundmacher R.

Arch Ophthalmol. 2001 Oct;119(10):1487-91.

PMID:
11594949
[PubMed - indexed for MEDLINE]
20.

Pretreatment with topical 0.1% (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine inhibits adenovirus type 5 replication in the New Zealand rabbit ocular model.

Gordon YJ, Romanowski E, Araullo-Cruz T, De Clercq E.

Cornea. 1992 Nov;11(6):529-33.

PMID:
1334824
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk